Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|August 29, 2018

Enhanced Analysis with New Triple Quadrupole Mass Spectrometer

The TSQ Fortis Triple Quadrupole Mass Spectrometer from Thermo Fisher Scientific offers fast, robust liquid chromatography-mass spectrometry (LC-MS/MS) analysis for clinical research laboratories.

The Thermo Scientific TSQ Fortis Triple Quadrupole Mass Spectrometer allows clinical research laboratory scientists who face challenges in developing reproducible and reliable methods for the quantitation of analytes in biological matrices to achieve higher productivity while meeting laboratory demands.

The mass spectrometer is suited for applications that demand speed, robustness, and sensitivity for the quantitation of compounds in biological matrices by users with varying levels of expertise.

Features include:

  • Active Ion Management Plus, which enables high precision for every molecule type in complex matrices

  • Selected reaction monitoring capability with ion transmission efficiency, which is designed for simultaneous, reliable quantitation of all components in a complex matrix for high instrument throughput

  • An ion optics design that allows for simple, tool-free maintenance

  • Matrix Separator Ion Guide for maximum robustness while minimizing ion loss

  • Simplified workflows that offer efficiency without compromising data quality from sample injection to report generation

  • Intuitive drag-and-drop method editor software for simple method development and operation through application-based templates.

The instrument’s platform is built on a foundation of shared hardware and software components and can be paired with a range of high-performance Thermo Scientific liquid chromatography systems. This pairing capability enables users to go from single-sample-based experiments to validation to routine high-volume screening and quantification, the company reports.

Source: Thermo Fisher Scientific


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.